Stoke Therapeutics Launches Public Offering for Clinical Development
Company Announcements

Stoke Therapeutics Launches Public Offering for Clinical Development

Stoke Therapeutics Inc (STOK) has provided an announcement.

Stoke Therapeutics, Inc. has launched a public offering, selling over 5.5 million shares and issuing pre-funded warrants for about 3.7 million shares, with J.P. Morgan Securities coordinating as the underwriter. The shares are priced at $13.50 each, while the warrants are slightly less. The company anticipates a net gain of around $119.8 million from the sale, before underwriting costs and other expenses. These funds are earmarked for research, clinical development of product candidates like STK-001 and STK-002, and other corporate expenses, with the offering expected to close on April 2, 2024.

For a thorough assessment of STOK stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyStoke Therapeutics assumed with an Outperform at Leerink
TheFlyStoke Therapeutics files automatic mixed securities shelf
Radhika Saraogi3 Best Stocks to Buy Now, 9/11/2024, According to Top Analysts 
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App